Lung Cancer Clinical Trial

REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

Summary

The primary objective of the dose escalation (phase 1) part of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer (NSCLC).

The primary objective of the dose expansion (phase 2) part of the study is to assess preliminary anti-tumor activity of REGN5093 as measured by the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Histologically confirmed NSCLC that is at advanced stage. Advanced is defined as unresectable or metastatic disease. Patients must have exhausted all approved available therapies appropriate for the patient.
Has available archival tumor tissue, unless discussed with the medical monitor.
Willing to provide tumor tissue from newly obtained biopsy. Newly obtained biopsies at screening are required unless medically contra-indicated and discussed with the medical monitor. For patients in expansion cohorts, biopsies should be taken from tumor site which has not been irradiated previously and is not the only measurable target lesion.
Previously documented presence of MET alterations: either MET-exon14 gene mutation and/or MET gene amplification, and/or elevated MET protein expression, as defined in the protocol.

Key Exclusion Criteria:

Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device within 2 weeks or 5 half-lives of the prior treatment whichever is shorter with a minimum of 7 days from the first dose of study therapy
Has not yet recovered (i.e. grade ≤1 or baseline) from any acute toxicities resulting from prior therapy except as described in the protocol
Has received radiation therapy or major surgery within 14 days of first administration of study drug or has not recovered (i.e. grade ≤1 or baseline) from AEs, except for laboratory changes as described in the protocol and patients with grade ≤2 neuropathy
For expansion cohorts only: prior treatment with MET-targeted biologic therapy (function-blocking antibodies or ADCs)
For expansion cohorts only (except cohort 1A) prior treatment with any MET-targeted agent including small molecule tyrosine kinase inhibitors eg, crizotinib, capmatinib, tepotinib, as defined in the protocol
Untreated or active primary brain tumor, CNS metastases, leptomeningeal disease or spinal cord compression as defined in the protocol

Note: Other protocol defined Inclusion/Exclusion criteria apply.

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

111

Study ID:

NCT04077099

Recruitment Status:

Recruiting

Sponsor:

Regeneron Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 30 Locations for this study

See Locations Near You

Regeneron Research Facility
Birmingham Alabama, 35294, United States
Regeneron Research Facility
Orange California, 92868, United States
Regeneron Research Facility
Washington District of Columbia, 20007, United States
Regeneron Research Facility
Tampa Florida, 33612, United States
Regeneron Research Facility
Lexington Kentucky, 40536, United States
Regeneron Research Facility
Boston Massachusetts, 02215, United States
Regeneron Research Facility
Detroit Michigan, 48202, United States
Regeneron Research Facility
Saint Louis Missouri, 63110, United States
Regeneron Research Facility
New York New York, 10016, United States
Regeneron Research Facility
New York New York, 10029, United States
Regeneron Research Facility
New York New York, 10065, United States
Regeneron Research Facility
Durham North Carolina, 27710, United States
Regeneron Research Facility
Oklahoma City Oklahoma, 73104, United States
Regeneron Research Facility
Philadelphia Pennsylvania, 19111, United States
Regeneron Research Facility
Pittsburgh Pennsylvania, 15232, United States
Regeneron Research Facility
Dallas Texas, 75390, United States
Regeneron Research Facility
Houston Texas, 77030, United States
Regeneron Research Facility
Bordeaux Cedex 9 , 33076, France
Regeneron Study Site
Caen cedex , 14076, France
Regeneron Research Facility
Dijon Cedex , 21034, France
Regeneron Research Facility
Grenoble , 38043, France
Regeneron Research Facility
Montpellier , 34295, France
Regeneron Research Facility
Rennes Cedex 9 , 35033, France
Regeneron Research Facility
Gyeonggi do Gyeonggi, 10408, Korea, Republic of
Regeneron Research Facility
Suwon Gyeonggi, 16247, Korea, Republic of
Regeneron Research Facility
Seoul , 03080, Korea, Republic of
Regeneron Research Facility
Seoul , 03722, Korea, Republic of
Regeneron Research Facility
Seoul , 05505, Korea, Republic of
Regeneron Research Facility
Seoul , 06351, Korea, Republic of
Regeneron Research Facility
Seoul , 06591, Korea, Republic of

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

111

Study ID:

NCT04077099

Recruitment Status:

Recruiting

Sponsor:


Regeneron Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.